HomeCompareSHLM vs PFE

SHLM vs PFE: Dividend Comparison 2026

SHLM yields 4.55% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHLM wins by $637.7K in total portfolio value
10 years
SHLM
SHLM
● Live price
4.55%
Share price
$44.00
Annual div
$2.00
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$687.2K
Annual income
$408,119.20
Full SHLM calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SHLM vs PFE

📍 SHLM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHLMPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHLM + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHLM pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHLM
Annual income on $10K today (after 15% tax)
$386.36/yr
After 10yr DRIP, annual income (after tax)
$346,901.32/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SHLM beats the other by $324,581.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHLM + PFE for your $10,000?

SHLM: 50%PFE: 50%
100% PFE50/50100% SHLM
Portfolio after 10yr
$368.4K
Annual income
$217,188.96/yr
Blended yield
58.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SHLM
No analyst data
Altman Z
12.1
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHLM buys
0
PFE buys
0
No recent congressional trades found for SHLM or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHLMPFE
Forward yield4.55%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR51.4%13.2%
Portfolio after 10y$687.2K$49.6K
Annual income after 10y$408,119.20$26,258.71
Total dividends collected$636.4K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SHLM vs PFE ($10,000, DRIP)

YearSHLM PortfolioSHLM Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,388$688.18$9,153$693.39+$2.2KSHLM
2$13,294$1,108.92$8,593$849.25+$4.7KSHLM
3$16,057$1,831.69$8,336$1,066.78+$7.7KSHLM
4$20,311$3,130.27$8,437$1,384.80+$11.9KSHLM
5$27,335$5,602.71$9,013$1,875.40+$18.3KSHLM
6$39,918$10,669.33$10,306$2,680.72+$29.6KSHLM
7$64,758$22,045.76$12,820$4,101.38+$51.9KSHLM
8$119,896$50,604.82$17,673$6,826.70+$102.2KSHLM
9$260,858$132,569.79$27,543$12,591.86+$233.3KSHLM
10$687,238$408,119.20$49,560$26,258.71+$637.7KSHLM

SHLM vs PFE: Complete Analysis 2026

SHLMStock

A. Schulman, Inc. manufactures and supplies plastic compounds and resins. It offers custom performance colors, including standard and customized colors, organic and inorganic pigments, high chroma colors in translucent or opaque formats, and special effects. The company also provides engineered composites, such as bulk molding compounds, sheet molding compounds, and thick molding compounds, as well as engineered structural composite solutions for original equipment manufacturers and custom molders. In addition, it offers concentrates to enhance the performance, appearance, and processing of plastics for intended applications; additive solutions; and application solutions that minimize the use of plastics, or incorporate the use of recycled plastics or renewable-based polymers, as well as provides films for agriculture, packaging, and personal care and hygiene applications. Further, the company offers polymer solutions, which provide structural integrity; multi-component blends that include polyolefins, nylons, polyesters and elastomers, and others; and formulating know-how with fiber reinforcements, such as glass and carbon, nano-reinforcements, flame retardants, impact modifiers, and UV stabilization. Additionally, it offers size reduction services; specialty powders for rotational molding, oil and gas additives, and sports and leisure products; jet milling services used for products requiring fine particle size; and cryogenic milling services. The company also buys, repackages, and resells polymers for processing types, such as injection molding, blow molding, thermoforming, and film and sheet extruding. It serves packaging, mobility, building and construction, electronics and electrical, agriculture, personal care and hygiene, custom services, sports, home, and leisure markets worldwide. The company was founded in 1928 and is headquartered in Fairlawn, Ohio. As of August 21, 2018, A. Schulman, Inc. operates as a subsidiary of LyondellBasell Industries N.V.

Full SHLM Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SHLM vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHLM vs SCHDSHLM vs JEPISHLM vs OSHLM vs KOSHLM vs MAINSHLM vs JNJSHLM vs MRKSHLM vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.